Navigation Links
Alliance Biosciences Announces Trade Mission to Singapore with Speaker Presentation at International Lab Design Seminar
Date:1/7/2009

RICHMOND, Va., Jan. 7 /PRNewswire/ -- Dr. Ryan Burnette, Director of Alliance Biosciences will lead a trade mission to Singapore January 19, 2009 through January 23, 2009. Dr. Burnette will be promoting the need for international accreditation processes for high-containment biomedical labs as a lynchpin to an effective biosecurity and biosafety preparedness program.

"I am very excited to visit Singapore, a progressive country that has embraced the need for well-designed and operated containment labs and operations," said Dr. Burnette. "I look forward to meeting with academic, governmental and private sector leaders to discuss ways to utilize solid accreditation standards as a foundation for best practices in research and manufacturing, and to partially mitigate the risks of bio-terrorism."

During his visit, Dr. Burnette will speak at the Lab Design Seminar taking place January 19th - 20th at Biopolis, the biomedical R&D hub at one-north, a 200 hectare vibrant hotspot for R&D innovation and test-bedding. Organized by JTC Corporation, the master developer for one-north, the inaugural seminar, a first for Singapore, will be the ideal networking forum for international thought leaders, scientists, developers and other professionals to come together to exchange invaluable insights and experiences on specialty lab design.

"Biopolis has seeded the Biomedical research industry in Singapore and garnered international attention," said Philip Su, Assistant Chief Executive Officer, JTC Corporation. "We are privileged to have Dr. Burnette speak at this event, which will encourage greater sharing between design professionals from all over the world, and break boundaries between different international practices."

On January 20th at 4:15pm, Dr. Burnette will deliver a presentation titled "Working Toward Accreditation Standards". The speech will highlight the significant need for internatio
'/>"/>

SOURCE Alliance Biosciences
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Imugene and Merial Establish Strategic Alliance
2. PAREXEL Establishes Alliance with SITS Network of Clinical Sites Specializing in Stroke Studies
3. SciQuest Announces Strategic Alliance with QIAGEN
4. Universal Bioenergy, Inc. Seeks Algae Feedstock Companies for Acquisition, Alliance, and Joint Venture Opportunities for Biodiesel Production
5. Environmental Power Corporation and Organix, Inc. Establish Alliance to Produce High Value Soil Amendment Products
6. Commonwealth Care Alliance Selects Casenet To Unify Patient Information and Improve Care for Massachusetts Members
7. PharmAthene and Panacea Biotec Ltd. Establish Strategic Alliance in Biodefense and Emerging Infectious Diseases
8. Swedish Neuroscience Institute and Institute for Systems Biology in Seattle Form Alliance to Learn More about Brain Diseases
9. Neptune Technologies and Marine Life Sciences enter worldwide distribution alliance with Weider Global Nutrition
10. GlaxoSmithKline and Cellzome Announce Major Strategic Alliance
11. Campbell Alliance Sales Practice to Present at CBIs Leadership Summit on Evolving the Pharma Sales Model
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 2Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 4RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 5RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 6Alberta companies delivering new products to the health & medical marketplace 2JourneyLite of Houston Now Offering Sleeve Gastrectomy 2